Healthcare / BiotechnologyStockholm
$7.33
-0.13 (-1.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-36.3M · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-150.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-54.7M · FCF $-38.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-54.7M | $-54.7M | $-41.8M | $-20.4M | $-17.2M |
| EBITDA | $-44.7M | $-44.7M | $-32.9M | $-20.0M | $-17.1M |
| EPS | -0.31 | -0.31 | -0.25 | -0.18 | -1.50 |
| Balance Sheet | |||||
| Current Ratio | 3.12 | 3.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.9M | $-38.9M | $-36.3M | $-29.6M | $-20.3M |
| Returns | |||||
| ROE | -150.5% | -150.5% | -64.9% | -97.6% | -45.2% |
| Valuation | |||||
| P/B | 35.86 | 35.86 | 9.63 | 17.35 | 11.18 |
| Growth & Yield | |||||
| EPS Growth | -23.4% | -23.4% | -36.7% | 87.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+76.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.25 → -0.31
Residual
+76.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.